Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis

References

• O’Reilly T, McSheehy PM. Biomarker development for the clinical activity of the mTOR inhibitor Everolimus (RAD001): processes, limitations, and further proposals. Transl Oncol 2010;3(2):65-79
   PubMedGoogle Scholar
• Houghton PJ. Everolimus. Clin Cancer Res 2010;16(5):1368-72
   PubMed Web of Science ®Google Scholar
• Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28(1):69-76
   PubMed Web of Science ®Google Scholar
• Ravaud A, Urva SR, Grosch K, et al. Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology. Eur J Cancer 2014;50(3):486-95
   PubMedGoogle Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363(19):1801-11
   PubMed Web of Science ®Google Scholar
• Afinitor (Everolimus) tablets for mucocutaneous administration. summary of product characteristics Novartis Pharma AG; Stein, Switzerland: 2012
   Google Scholar
• Huober J, Fasching PA, Hanusch C, et al. Neoadjuvant chemotherapy with paclitaxel and Everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44). Eur J Cancer 2013;49(10):2284-93
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62(10):1006-12
   PubMed Web of Science ®Google Scholar
• National cancer institute, common toxicity criteria. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378(9808):2005-12
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):514-23
   PubMed Web of Science ®Google Scholar
• Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349(9):847-58
   PubMed Web of Science ®Google Scholar
• Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002;3(2):295-304
   PubMedGoogle Scholar
• Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012;2(5):74-83
   PubMedGoogle Scholar
• Rugo HS, Pritchard KI, Gnant M, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014;25(4):808-15
   PubMed Web of Science ®Google Scholar
• Efficacy of secukinumab compared to ustekinumab in patients with plaque-type psoriasis. Available from: http://clinicaltrials.gov/ct2/show/NCT02015559 [Last accessed 24 June 2014]
   Google Scholar
• Safety and efficacy of OMS643762 in subjects with Huntington’s disease. Available from: http://clinicaltrials.gov/ct2/show/NCT02069093 [Last accessed 24 June 2014]
   Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Rugo H, Yao J, Hortobagyi G, et al. Meta-analysis of stomatitis incidence in everolimus (EVE) clinical studies and its relationship with efficacy. J Clin Oncol Meeting Abstracts 2014;32:15 Suppl 645
   Google Scholar
• Pengel LH, Liu LQ, Morris PJ. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011;24(12):1216-30
   PubMedGoogle Scholar
• Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of Everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125-32
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013;31(31):3935-43
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381(9869):817-24
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of Everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012;30(22):2718-24
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of Everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant Everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27(16):2630-7
   PubMed Web of Science ®Google Scholar